Copenhagen Health Science Partners Celebrates One-Year Anniversary
The research partnership between UCPH and the Capital Region of Denmark, which pairs clinicians with laboratory researchers in the hope of shortening the path from research to treatment, can celebrate its one-year anniversary today – while getting ready to expand. One of the first group leaders in the partnership takes stock of the development so far.
At Copenhagen Health Science Partners (CHSP) four Clinical Academic Groups (CAGs) are striving to develop treatment methods and ensure that the latest new health science research can benefit the patients faster. Today they can celebrate their one-year anniversary.
The four CAGs all consist of both laboratory researchers and clinical researchers and focus on diseases of great social relevance. They are called Allergy, Physical Activity and Sport in Clinical Medicine, Precision Diagnostics in Cardiology, and Translational Hematology.
Collaboration with Ambitions to Grow
One of the CAGs that have benefitted from the collaboration is Translational Hematology, which strives to improve the outcome of treatment for blood cancer. In addition to the collaboration between UCPH and the Capital Region of Denmark, the CAG also cooperates with the other departments of hematology in Zealand.
‘There is a long-standing tradition in our field for competition. But the CAG has had a very positive effect, among other things because we can do larger projects together in order to treat more patients’, says Head of the CAG Kirsten Grønbæk, Professor and Consultant Doctor at the Department of Hematology, Rigshospitalet and the Biotech Research & Innovation Centre, Faculty of Health and Medical Sciences.
Right now the CAG is focussing on the blood diseases acute myeloid leukaemia and myelodysplastic syndrome, but the ambition is to expand with more clinicians and researchers specialising in other types of
Translational Hematology is also busy preparing study programmes for the next generation of both clinical researchers and basic researchers within the area of blood cancer. In the long run this will help strengthen and improve the treatment for blood cancer.
‘Our main vision for the future is naturally to improve the conditions of the patients. In the long run we hope to help develop treatments specifically targeted at the cancer stem cells causing recurrences of leukaemia’, says Kirsten Grønbæk.
Ready to Expand
On 28 June the present CAGs will be joined by four new CAGs, which will also be characterised by university-hospital collaboration. The new CAGs will be introduced on 28 June in the Maersk Tower.
Professor Kirsten Grønbæk
+45 35 45 60 86
Communications Officer Mathilde Sofia Egede Andersen
+45 23 64 94 25